Amphastar Pharmaceuticals (AMPH) Equity Average (2014 - 2026)

Amphastar Pharmaceuticals' Equity Average history runs 13 years deep, the most recent figure standing at $781.1 million for Q1 2026.

• In Q1 2026, Equity Average rose 5.3% year-over-year to $781.1 million; the TTM figure through Mar 2026 stood at $781.1 million (up 5.3% YoY), while the FY2025 annual figure was $760.6 million, up 10.89% from the prior year.
• Equity Average was $781.1 million for Q1 2026 at Amphastar Pharmaceuticals, roughly flat from $782.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $782.8 million in Q4 2025 to a low of $462.5 million in Q1 2022.
• Historically, Equity Average has averaged $642.0 million across 5 years, with a median of $655.9 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Equity Average advanced 2.82% in 2022, then advanced 21.79% in 2024.
• A 5-year view of Equity Average shows it stood at $516.9 million in 2022, then climbed by 19.42% to $617.3 million in 2023, then gained by 18.26% to $730.0 million in 2024, then grew by 7.23% to $782.8 million in 2025, then retreated by 0.21% to $781.1 million in 2026.
• The last three Equity Average figures came in at $781.1 million (Q1 2026), $782.8 million (Q4 2025), and $767.1 million (Q3 2025), per Business Quant data.